Study of belantamab mafodotin plus standard of care (SoC) in newly diagnosed multiple myeloma

Trial Identifier: 209664
Sponsor: GlaxoSmithKline
Start Date: December 2019
Primary Completion Date: June 2025
Study Completion Date: December 2026
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
AUSTRALIA, NSW Newcastle, NSW, AUSTRALIA, 2298
AUSTRALIA, VIC Clayton, VIC, AUSTRALIA, 3168
AUSTRALIA, VIC Fitzroy, VIC, AUSTRALIA, 3065
CANADA, AB Edmonton, AB, CANADA, T6G 1Z2
CANADA, ON London, ON, CANADA, N6A 5W9
FRANCE Poitiers, FRANCE, 86021
GERMANY Dresden, GERMANY, 01307
GERMANY Hamburg, GERMANY, 20246
GERMANY Schwerin, GERMANY, 19049
GERMANY Tuebingen, GERMANY, 72076
ITALY Bologna, ITALY, 40138
ITALY Meldola FC, ITALY, 47014
KOREA,_REPUBLIC_OF Seoul, KOREA,_REPUBLIC_OF, 03722
KOREA,_REPUBLIC_OF Seoul, KOREA,_REPUBLIC_OF, 137-701
KOREA,_REPUBLIC_OF SEOUL, KOREA,_REPUBLIC_OF, 03080
POLAND Lublin, POLAND, 20-081
POLAND Poznan, POLAND, 61-848
SPAIN Badalona, SPAIN, 08916
SPAIN Barcelona, SPAIN, 08036
SPAIN Madrid, SPAIN, 28027
SPAIN Malaga, SPAIN, 29010
SPAIN PamplonaNavarra, SPAIN, 31008
SPAIN Pozuelo de AlarcOn Madr, SPAIN, 28223
SPAIN Santander, SPAIN, 39008
UNITED_KINGDOM Leicester, UNITED_KINGDOM, LE1 5WW
UNITED_KINGDOM Oxford, UNITED_KINGDOM, OX3 7LE
UNITED_KINGDOM Southampton, UNITED_KINGDOM, SO16 6YD
UNITED_STATES, Kansas Westwood, Kansas, UNITED_STATES, 66205
UNITED_STATES, NC Charlotte, NC, UNITED_STATES, 28204
UNITED_STATES, WI Madison, WI, UNITED_STATES, 53792